

Xue-Li Bai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/481199/publications.pdf>

Version: 2024-02-01

124
papers

4,834
citations

101543

36
h-index

123424

61
g-index

127
all docs

127
docs citations

127
times ranked

7956
citing authors

#	ARTICLE	IF	CITATIONS
1	Construction of a human cell landscape at single-cell level. <i>Nature</i> , 2020, 581, 303-309.	27.8	695
2	Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. <i>Gut</i> , 2019, 68, 2019-2031.	12.1	230
3	Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis. <i>Cancer Research</i> , 2016, 76, 818-830.	0.9	225
4	Hypoxia-inducible factor-1 α /interleukin-1 β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment. <i>Hepatology</i> , 2018, 67, 1872-1889.	7.3	216
5	Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. <i>Genes and Development</i> , 2017, 31, 247-259.	5.9	207
6	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 72.	17.1	191
7	Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer. <i>Oncogene</i> , 2018, 37, 6105-6118.	5.9	119
8	VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 83.	17.0	118
9	Hypoxia-inducible factor-2 α promotes tumor progression and has crosstalk with Wnt/ β -catenin signaling in pancreatic cancer. <i>Molecular Cancer</i> , 2017, 16, 119.	19.2	97
10	USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity. <i>Cancer Immunology Research</i> , 2019, 7, 1580-1590.	3.4	94
11	Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent. <i>Scientific Reports</i> , 2016, 6, 23269.	3.3	90
12	Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β -catenin/TCF complex association via FOXO3a activation. <i>Oncotarget</i> , 2015, 6, 10350-10365.	1.8	84
13	Duct-to-Mucosa vs Invagination for Pancreaticojejunostomy after Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial from a Single Surgeon. <i>Journal of the American College of Surgeons</i> , 2016, 222, 10-18.	0.5	78
14	Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. <i>Cancer Letters</i> , 2019, 452, 237-243.	7.2	78
15	Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 134, 83-91.	2.5	73
16	Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. <i>Radiation Oncology</i> , 2018, 13, 188.	2.7	67
17	Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 196-203.	4.1	61
18	Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression. <i>World Journal of Gastroenterology</i> , 2018, 24, 3500-3512.	3.3	58

#	ARTICLE	IF	CITATIONS
19	Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 231-245.	3.4	58
20	Hypoxia-inducible factor 1 α expression and its clinical significance in pancreatic cancer: A meta-analysis. <i>Pancreatology</i> , 2014, 14, 391-397.	1.1	57
21	WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation. <i>Cancer Letters</i> , 2015, 361, 218-225.	7.2	55
22	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 227-252.	1.5	55
23	Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. <i>Hpb</i> , 2020, 22, 821-832.	0.3	54
24	Contrast-enhanced CT radiomics for preoperative evaluation of microvascular invasion in hepatocellular carcinoma: A two-center study. <i>Clinical and Translational Medicine</i> , 2020, 10, e111.	4.0	53
25	NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. <i>Nature Communications</i> , 2021, 12, 4536.	12.8	51
26	Induced phase separation of mutant NF2 imprisons the cGAS-STING machinery to abrogate antitumor immunity. <i>Molecular Cell</i> , 2021, 81, 4147-4164.e7.	9.7	51
27	Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors. <i>Scientific Reports</i> , 2015, 5, 13664.	3.3	49
28	G protein-coupled estrogen receptor deficiency accelerates liver tumorigenesis by enhancing inflammation and fibrosis. <i>Cancer Letters</i> , 2016, 382, 195-202.	7.2	47
29	One-stage laproendoscopic procedure versus two-stage procedure in the management for gallstone disease and biliary duct calculi: a systemic review and meta-analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 3582-3590.	2.4	47
30	Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. <i>Cancer Letters</i> , 2017, 406, 22-26.	7.2	47
31	Tumor-derived exosomes promote tumor self-seeding in hepatocellular carcinoma by transferring miRNA-25-5p to enhance cell motility. <i>Oncogene</i> , 2018, 37, 4964-4978.	5.9	47
32	Liquid biopsy in pancreatic cancer: the beginning of a new era. <i>Oncotarget</i> , 2018, 9, 26900-26933.	1.8	47
33	Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. <i>British Journal of Cancer</i> , 2019, 121, 786-795.	6.4	47
34	Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 152.	3.7	46
35	Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1 α -VEGF mediated angiogenesis. <i>Cancer Letters</i> , 2014, 355, 281-287.	7.2	44
36	ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition. <i>Cancer Letters</i> , 2016, 377, 140-148.	7.2	40

#	ARTICLE	IF	CITATIONS
37	A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. <i>Hpb</i> , 2020, 22, 795-808.	0.3	39
38	The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway. <i>Cancer Letters</i> , 2016, 380, 98-105.	7.2	38
39	Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1805-1815.	4.1	36
40	The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 95-100.	1.1	32
41	Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies. <i>World Journal of Gastroenterology</i> , 2020, 26, 3720-3736.	3.3	32
42	The implementation of an enhanced recovery after surgery (ERAS) program following pancreatic surgery in an academic medical center of China. <i>Pancreatology</i> , 2016, 16, 665-670.	1.1	31
43	Roles of Sphincter of Oddi Laxity in Bile Duct Microenvironment in Patients with Cholangiolithiasis: From the Perspective of the Microbiome and Metabolome. <i>Journal of the American College of Surgeons</i> , 2016, 222, 269-280e10.	0.5	31
44	Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2062-2072.	4.1	29
45	External validation of alternative fistula risk score (a-FRS) for predicting pancreatic fistula after pancreatoduodenectomy. <i>Hpb</i> , 2020, 22, 58-66.	0.3	28
46	lncRNA <i>POIR</i> promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging <i>miR-182</i> . <i>Journal of Cellular Biochemistry</i> , 2021, 122, 130-142.	2.6	28
47	Glucose Metabolism: The Metabolic Signature of Tumor Associated Macrophage. <i>Frontiers in Immunology</i> , 2021, 12, 702580.	4.8	27
48	Meta-analysis of invagination and duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: An update. <i>International Journal of Surgery</i> , 2016, 36, 240-247.	2.7	25
49	Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors. , 2022, 10, e003982.		25
50	<i>B7H5/CD28</i> is a costimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma. <i>Cancer Science</i> , 2019, 110, 530-539.	3.9	24
51	ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-16.	1.5	21
52	Association of Modified <i>FOLFIRINOX</i> Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. <i>Oncologist</i> , 2019, 24, 301.	3.7	21
53	Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. <i>Frontiers in Microbiology</i> , 2021, 12, 761836.	3.5	21
54	Molecular Profiling-Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges. <i>Frontiers in Oncology</i> , 2020, 10, 532403.	2.8	20

#	ARTICLE	IF	CITATIONS
55	Salvage Liver Transplant versus Primary Liver Transplant for Patients with Hepatocellular Carcinoma. <i>Annals of Transplantation</i> , 2018, 23, 524-545.	0.9	20
56	Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 56.	8.6	20
57	Long-term results of laparoscopic fenestration for patients with congenital liver cysts. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2007, 6, 600-3.	1.3	20
58	Non-cytoplasmic PD-L1: An atypical target for cancer. <i>Pharmacological Research</i> , 2021, 170, 105741.	7.1	19
59	Fate mapping analysis reveals a novel murine dermal migratory Langerhans-like cell population. <i>ELife</i> , 2021, 10, .	6.0	18
60	OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 26230-26241.	1.8	18
61	Sister Mary Joseph's nodule as a first sign of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2012, 18, 6686.	3.3	18
62	The role of imaging in prediction of post-hepatectomy liver failure. <i>Clinical Imaging</i> , 2018, 52, 137-145.	1.5	17
63	Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget. <i>Cellular and Molecular Immunology</i> , 2020, 17, 677-679.	10.5	17
64	Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression. <i>Frontiers in Immunology</i> , 2020, 11, 2076.	4.8	17
65	Evaluation of Intra-Tumoral Vascularization in Hepatocellular Carcinomas. <i>Frontiers in Medicine</i> , 2020, 7, 584250.	2.6	16
66	Pancreatic cystic neoplasms: a review of preoperative diagnosis and management. <i>Journal of Zhejiang University: Science B</i> , 2013, 14, 185-194.	2.8	15
67	Calreticulin couples with immune checkpoints in pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, 36-44.	4.0	15
68	Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. <i>EBioMedicine</i> , 2022, 78, 103958.	6.1	15
69	Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes. <i>Science Advances</i> , 2022, 8, .	10.3	15
70	Sphincter of Oddi laxity alters bile duct microbiota and contributes to the recurrence of choledocholithiasis. <i>Annals of Translational Medicine</i> , 2020, 8, 1383-1383.	1.7	14
71	Prediction of postoperative pancreatic fistula using a nomogram based on the updated definition. <i>Annals of Surgical Treatment and Research</i> , 2020, 98, 72.	1.0	13
72	LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation. <i>Tumor Biology</i> , 2016, 37, 7277-7286.	1.8	12

#	ARTICLE	IF	CITATIONS
73	A preoperative nomogram predicts prognosis of up front resectable patients with pancreatic head cancer and suspected venous invasion. <i>Hpb</i> , 2018, 20, 1034-1043.	0.3	12
74	Factors associated with failure of enhanced recovery after surgery program in patients undergoing pancreaticoduodenectomy. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2020, 19, 51-57.	1.3	12
75	Oncolytic virotherapy in hepato-bilio-pancreatic cancer: The key to breaking the log jam?. <i>Cancer Medicine</i> , 2020, 9, 2943-2959.	2.8	12
76	Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. <i>Molecular Oncology</i> , 2020, 14, 1966-1977.	4.6	12
77	Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 485-492.	1.1	12
78	Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial location. <i>Radiation Oncology</i> , 2016, 11, 138.	2.7	11
79	Laparoscopic Spleen-Preserving Distal Pancreatectomy (LSPDP) with Preservation of Splenic Vessels: An Inferior-Posterior Approach. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	1.5	11
80	Surgical management and outcome of grade-C pancreatic fistulas after pancreaticoduodenectomy: A retrospective multicenter cohort study. <i>International Journal of Surgery</i> , 2019, 68, 27-34.	2.7	11
81	Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. <i>Npj Precision Oncology</i> , 2020, 4, 29.	5.4	11
82	Eating self for not be eaten: Pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 94.	17.1	11
83	Novel deep learning radiomics model for preoperative evaluation of hepatocellular carcinoma differentiation based on computed tomography data. <i>Clinical and Translational Medicine</i> , 2021, 11, e570.	4.0	11
84	Hook1 inhibits malignancy and epithelial-mesenchymal transition in hepatocellular carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831771109.	1.8	10
85	Preoperative prediction of peripancreatic vein invasion by pancreatic head cancer. <i>Cancer Imaging</i> , 2018, 18, 49.	2.8	10
86	Pancreas-preserving management of grade-C pancreatic fistula and a novel bridging technique for repeat pancreaticojejunostomy: An observational study. <i>International Journal of Surgery</i> , 2018, 52, 243-247.	2.7	9
87	The AKT-independent MET-V-ATPase-MTOR axis suppresses liver cancer vaccination. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 122.	17.1	9
88	Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. <i>Oncogene</i> , 2021, 40, 3136-3151.	5.9	9
89	Autologous bone marrow transplantation in decompensated liver: Systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2015, 21, 8697.	3.3	9
90	Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: The CISP3 trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 560-560.	1.6	9

#	ARTICLE	IF	CITATIONS
91	Duct-to-mucosa versus invagination pancreaticojejunostomy after pancreaticoduodenectomy: a meta-analysis. <i>Chinese Medical Journal</i> , 2013, 126, 4340-7.	2.3	9
92	Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy. <i>EBioMedicine</i> , 2022, 79, 103987.	6.1	9
93	Patients with pancreatic cystic neoplasms can benefit from management of multidisciplinary team: Experience from a Chinese academic center. <i>Pancreatology</i> , 2018, 18, 799-804.	1.1	8
94	Predicting surgical site infections using a novel nomogram in patients with hepatocellular carcinoma undergoing hepatectomy. <i>World Journal of Clinical Cases</i> , 2019, 7, 2176-2188.	0.8	8
95	Liver Transplantation from Voluntary Organ Donor System in China: A Comparison between DBD and DCD Liver Transplants. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-7.	1.5	7
96	Reviving the role of MET in liver cancer therapy and vaccination: an autophagic perspective. <i>Oncolmmunology</i> , 2020, 9, 1818438.	4.6	7
97	Carcinosarcoma of the pancreas: comprehensive clinicopathological and molecular characterization. <i>Hpb</i> , 2020, 22, 1590-1595.	0.3	7
98	Acute iatrogenic Budd-Chiari syndrome following hepatectomy for hepatolithiasis: A report of two cases. <i>World Journal of Gastroenterology</i> , 2013, 19, 5763.	3.3	7
99	Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 862154.	2.8	7
100	Surveillance and management for serous cystic neoplasms of the pancreas based on total hazardsâ€”a multi-center retrospective study from China. <i>Annals of Translational Medicine</i> , 2019, 7, 807-807.	1.7	6
101	A nomogram for prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, e18490.	1.0	6
102	Role of Collateral Venous Circulation in Prevention of Sinistral Portal Hypertension After Superior Mesenteric-Portal Vein Confluence Resection during Pancreaticoduodenectomy: a Single-Center Experience. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2054-2061.	1.7	6
103	Outcomes of liver transplantation using moderately steatotic liver from donation after cardiac death (DCD). <i>Annals of Translational Medicine</i> , 2020, 8, 1188-1188.	1.7	6
104	Oncolytic virus combined with traditional treatment versus traditional treatment alone in patients with cancer: a meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1901-1913.	2.2	6
105	Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis. <i>Hpb</i> , 2021, 23, 1427-1438.	0.3	6
106	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. <i>Frontiers in Oncology</i> , 2020, 10, 590058.	2.8	5
107	A Seven-Gene Signature to Predict Prognosis of Patients With Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 728476.	2.3	5
108	Combined targeted therapy and immunotherapy for cancer treatment. <i>World Journal of Clinical Cases</i> , 2021, 9, 7643-7652.	0.8	5

#	ARTICLE	IF	CITATIONS
109	Liver Transplantation for Alcohol-Related Liver Disease (ARLD): An Update on Controversies and Considerations. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-6.	1.9	4
110	Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity. <i>Frontiers in Oncology</i> , 2020, 10, 1289.	2.8	4
111	A preoperative nomogram predicts prognosis of patients with hepatocellular carcinoma after liver transplantation: a multicenter retrospective study. <i>BMC Cancer</i> , 2021, 21, 280.	2.6	4
112	Probable sirolimus-induced rupture of arterial anastomosis after liver transplantation in a patient intolerant of tacrolimus. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 398-400.	1.3	3
113	Combinational therapy targeting the MET-mTOR-ROS loop disrupts mitochondrial autoregulatory machinery of liver cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e237.	4.0	3
114	A female surgeon's thoughts on gender attributes in surgery. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 370-372.	1.5	3
115	Multiplex imaging reveals the architecture of the tumor immune microenvironment. <i>Cancer Biology and Medicine</i> , 2021, 18, 949-954.	3.0	3
116	Preliminary data of a prospective study on the safety and efficacy of donafinib combined with anti-PD-1 antibody as adjuvant therapy for patients with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16131-e16131.	1.6	3
117	TALENTop: A multicenter, randomized study evaluating the efficacy and safety of hepatic resection for selected hepatocellular carcinoma with macrovascular invasion after initial atezolizumab plus bevacizumab treatment.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4175-TPS4175.	1.6	3
118	Randomized phase II trial of neoadjuvant chemotherapy with modified FOLFIRINOX versus modified FOLFIRINOX and PD-1 antibody for borderline resectable and locally advanced pancreatic cancer (the Tj ETQq0 0 OrqBT /Overlock 10 Tf		
119	Fate of Surgical Patients with Small Nonfunctioning Pancreatic Neuroendocrine Tumors: An International Study Using Multi-Institutional Registries. <i>Cancers</i> , 2022, 14, 1038.	3.7	2
120	A Case Report on Successful Liver Transplantation from a Donor with Polycystic Liver. <i>Indian Journal of Surgery</i> , 2014, 76, 405-407.	0.3	0
121	Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. <i>Surgery</i> , 2018, 164, 1392.	1.9	0
122	Development of a radiomics nomogram based on the CE-CT features to predict the survival of upfront resectable patients with pancreatic head cancer and suspected venous invasion.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15760-e15760.	1.6	0
123	Pancreatic cancer: Assessment of neoadjuvant chemotherapy outcome based on radiomics of pretreatment computed tomography.. <i>Journal of Global Oncology</i> , 2019, 5, 56-56.	0.5	0
124	Commentary on "The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma". <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 288-291.	1.5	0